RiboNova, Inc.

RiboNova, Inc. is a biopharmaceutical company founded in 2011, with a primary focus on developing treatments for mitochondrial disease and other serious rare diseases. The company's flagship asset, R007, is a Phase-2 ready small molecule drug designed to address all forms of genetically-confirmed mitochondrial disease. Additionally, RiboNova has a tRNA discovery program that targets defective transfer RNAs, offering potential treatment options for a range of human diseases. The burden of mitochondrial disease is severe, with an estimated 75,000 people affected in the US, and high morbidity and mortality rates, especially in children. Despite the significant impact on patients and the healthcare system, there are currently no FDA-approved drugs for mitochondrial disease. RiboNova's approach is notable for its innovative focus on targeting the underlying genetic causes of the disease, using DNA sequencing and a proprietary drug discovery platform to develop precision medicines. One of the company's key strengths lies in its commitment to addressing the unmet needs of patients suffering from mitochondrial diseases. RiboNova's strategic positioning within the Lankenau Institute for Medical Research near Philadelphia also provides access to valuable resources and expertise in the biopharmaceutical field. With a $25.00K Venture Round investment in March 2019, the company is positioned for further growth and potential breakthroughs in the treatment of mitochondrial and other rare diseases.